close

For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Nearly 15 percent of Fenwick partners named America's Leading Lawyers for Business by Chambers USA and Chambers Global
  • Selected as a "Go-To" law firm by in-house legal departments at Fortune 500 companies in Corporate Counsel magazine
  • Named to The National Law Journal's inaugural "Intellectual Property Hot List" for outstanding patent, copyright, trademark and IP litigation services

MORE >

We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041
650.988.8500

San Francisco Office
555 California Street
12th Floor
San Francisco, CA 94104
415.875.2300

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101
206.389.4510

Shanghai Office
36/F, Room 3690, Tower 2
Shanghai IFC
8 Century Avenue, Pudong
Shanghai 200120, China
+86 21 6062 6104

Stephen M. Graham

Industry Lead, Life Sciences

Partner, Corporate

icon partner 206.389.4520  

Office: Seattle

Stephen Graham is co-chair of Fenwick & West’s Life Sciences Practice and Managing Partner in the Seattle Office.

Stephen focuses his practice in the areas of private and public mergers and acquisitions, public offerings, private placements, and corporate governance matters, including advising boards of directors and audit, compensation and nominating/corporate governance committees, preparation and filing of periodic SEC reports, and other securities law compliance, including Sarbanes-Oxley Act matters and disclosure issues with respect to Rule 10b-5 and Regulation FD.

His diverse practice is focused on the representation of emerging and established high growth companies. Stephen has represented companies and investment banks in numerous initial public offerings, a wide variety of merger and acquisition transactions, and private offerings of debt and equity.

Stephen has been recognized by Chambers USA as one of the top corporate and mergers and acquisitions lawyers in Washington. He is also a “Super Lawyer” award recipient, 2000 - 2014, was ranked as one of the Top 100 Super Lawyers in 2005 by Washington Law & Politics, received the Top Lawyers award from Seattle Magazine in 2003, is listed in Who’s Who in America by Marquis Biographical Reference, has been recognized as one of The Best Lawyers in America, and is a member of Pi Sigma Alpha. Stephen was also recognized as a “Life Sciences Star” for his outstanding transactional work in Euromoney’s LMG Life Sciences 2012 and 2013.

In 2011, Stephen was appointed co-chairperson of the Securities and Exchange Commission’s Advisory Committee on Small and Emerging Companies. He is active in community affairs, currently serving on the Board of Directors of the Fred Hutchinson Cancer Research Center, the Institute for Systems Biology and the Washington Biotechnology & Biomedical Association, where he serves on the Executive Committee. He is also a member of the Bank of Montreal Financial Group Washington Advisory Board and serves on the Editorial Board of eHealth Law & Policy.

Prior to joining Fenwick & West, Stephen was a corporate partner with Orrick, Herrington & Sutcliffe LLP, where he was the chair of the global Corporate Practice Group.

Representative Transactions:

  • SonoSite, Inc. Stephen represented SonoSite, the leading provider of highly portable, all-digital ultrasound imaging devices, since its spin-off from ATL. He has represented SonoSite in a number of transactions, including its $200 million convertible note offering and its $995 million sale to FUJIFILM Holdings Corp.
  • Amnis Corporation. Stephen represented Amnis Corporation, a Seattle-based company that developed, manufactures and markets instrumentation for high speed cell imaging for research and diagnostic markets, in connection with its sale to EMD Millipore, the Life Science division of Merck KGaA of Germany.
  • ZymoGenetics, Inc. Stephen represented ZymoGenetics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic proteins, in connection with its $96 million confidentially managed public offering and its $885 million sale to Bristol-Myers Squibb.
  • Immunex Corporation. From its inception in 1981 and until its sale to Amgen in mid-2002, Stephen represented Immunex in a variety of corporate matters, including its initial public offering, its $750 million merger with American Cyanamid, public debt and equity offerings, securities law compliance, mergers and acquisitions and the successful defense of a hostile takeover attempt by American Home Products. He advised Immunex in its $3.2 billion public offering, the largest biotechnology stock offering at the time.
  • Teikoku Pharma USA, Inc. Stephen represented Teikoku Pharma USA, Inc., a world leader in high-quality drug delivery systems, in connection with its acquisition of Travanti Pharma Inc.
  • LipoSonix, Inc. Stephen represented LipoSonix, Inc. in connection with its $300 million sale to Medicis Pharmaceutical Corporation.
  • Advanced Medical Technologies. Stephen represented Advanced Medical Technologies, doing business as Blue Phantom, a global leader in the ultrasound medical imaging simulation business, in connection with its sale to CAE Healthcare.
  • Becton, Dickinson and Company. Stephen represented Becton, Dickinson and Company, a global medical technology company that manufactures medical supplies, devices, laboratory equipment and diagnostic products, in connection with its acquisition of Cytopeia Incorporated.
  • Cardiac Dimensions, Inc. Stephen has represented Cardiac Dimensions, a medical device company specializing in treating heart failure without open cavity surgery, in connection with general corporate matters and venture financings.

Representative Clients:

  • Accelerator Corporation
  • Acucela Inc.
  • Acylin Therapeutics, Inc.
  • Allozyne, Inc.
  • Amnis Corporation
  • Atigeo LLC
  • Authentex, Inc.
  • AWAK Technologies Pte Ltd. 
  • Cardeas Pharma Corp.
  • Cardiac Dimensions, Inc.
  • Cervel Neurotech, Inc.
  • Corixa Corporation
  • Corus Pharma, Inc.
  • FUJIFILM Holdings Corporation 
  • ICOS Corporation
  • Immunex Corporation
  • InControl Inc.
  • Institute for Systems Biology
  • LipoSonix, Inc.
  • NaviSonics, Inc.
  • SonoSite, Inc.
  • Teikoku Pharma USA, Inc.
  • Theraclone Sciences, Inc.
  • VLST Corporation
  • WatchGuard Technologies, Inc.
  • ZymoGenetics, Inc.
  •  

 

About Steve